The FKBP51-glucocorticoid receptor balance in stress-related mental disorders

Current Molecular Pharmacology

Volumn 9, Issue 2, 2015, Pages 126-140

  Fries, Gabriel R ^a,b   Gassen, Nils C ^a   Schmidt, Ulrike ^a   Rein, Theo ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

FKBP51; Glucocorticoid receptor; HPA axis; Mental disorders; Stress

Indexed keywords

FK 506 BINDING PROTEIN; GLUCOCORTICOID RECEPTOR; TACROLIMUS BINDING PROTEIN 5;

ADRENAL GLAND; ARTICLE; AUTOPHAGY; BIPOLAR DISORDER; CHROMATIN IMMUNOPRECIPITATION; COGNITIVE THERAPY; COPING BEHAVIOR; DEPRESSION; DNA METHYLATION; DNA POLYMORPHISM; DRUG DESIGN; ENHANCER REGION; FEEDBACK SYSTEM; FEMALE; GENE DELETION; GENE DUPLICATION; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HORMONE BINDING; INTRACELLULAR SIGNALING; MALE; MENTAL DISEASE; MENTAL STRESS; NONHUMAN; PHENOTYPE; PHYSIOLOGICAL STRESS; PLEIOTROPY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROTEIN INTERACTION; PSYCHOSIS; REPORTER GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SUICIDE; TRANSCRIPTION INITIATION SITE; TREATMENT RESPONSE; UPREGULATION; ANIMAL; DRUG DEVELOPMENT; HUMAN; MENTAL DISORDERS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

ANIMALS; DRUG DISCOVERY; HUMANS; MENTAL DISORDERS; MOLECULAR TARGETED THERAPY; RECEPTORS, GLUCOCORTICOID; STRESS, PHYSIOLOGICAL; TACROLIMUS BINDING PROTEINS;

EID: 84960952235     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467208666150519114435     Document Type: Article

References (188)

1. Nakao, K.; Myers, J.E.; Faber, L.E. Development of a monoclonal antibody to the rabbit 8.5S uterine progestin receptor. Can. J. Biochem. Cell Biol., 1985, 63, 33-40.
2. Smith, D.F.; Faber, L.E.; Toft, D.O. Purification of unactivated progesterone receptor and identification of novel receptorassociated proteins. J. Biol. Chem., 1990, 265, 3996-4003.
3. Sanchez, E.R. Hsp56: a novel heat shock protein associated with untransformed steroid receptor complexes 348. J. Biol. Chem., 1990, 265, 22067-22070.
4. Nair, S.C.; Rimerman, R.A.; Toran, E.J.; Chen, S.; Prapapanich, V.; Butts, R.N.; Smith, D.F. Molecular cloning of human FKBP51 and comparisons of immunophilin interactions with Hsp90 and progesterone receptor 200. Mol. Cell Biol., 1997, 17, 594-603.
5. Kang, C.B.; Hong, Y.; Dhe-Paganon, S.; Yoon, H.S. FKBP family proteins: immunophilins with versatile biological functions. Neurosignals, 2008, 16, 318-325.
6. Pirkl, F. Buchner, J. Functional analysis of the Hsp90-associated human peptidyl prolyl cis/trans isomerases FKBP51, FKBP52 and Cyp40. J. Mol. Biol., 2001, 308, 795-806.
7. Brinker, A.; Scheufler, C.; Von Der, Mulbe, Fleckenstein, B.; Herrmann, C.; Jung, G.; Moarefi, I.; Hartl, F.U. Ligand discrimi-nation by TPR domains. Relevance and selectivity of EEVDrecognition in Hsp70 x Hop x Hsp90 complexes. J. Biol. Chem., 2002, 277, 19265-19275.
8. Pratt, W.B. Toft, D.O. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr. Rev., 1997, 18, 306-360.
9. Silverstein, A.M.; Galigniana, M.D.; Kanelakis, K.C.; Radanyi, C.; Renoir, J.M.; Pratt, W.B. Different Regions of the Immunophilin FKBP52 Determine Its Association with the Glucocorticoid Receptor, hsp90, and Cytoplasmic Dynein. J. Biol. Chem.. 1999, 274, 36980-36986.
10. Storer, C.L.; Dickey, C.A.; Galigniana, M.D.; Rein, T.; Cox, M.B. FKBP51 and FKBP52 in signaling and disease. Trends Endocrinol. Metab., 2011, 22, 481-490.
11. Chrousos, G.P.; Renquist, D.; Brandon, D.; Eil, C.; Pugeat, M.; Vigersky, R.; Cutler, G.B.; Jr; Loriaux, D.L.; Lipsett, M.B. Glucocorticoid hormone resistance during primate evolution: receptormediated mechanisms. Proc. Natl. Acad. Sci. USA, 1982, 79, 2036-2040.
12. Chrousos, G.P.; Loriaux, D.L.; Tomita, M.; Brandon, D. D.; Renquist, D.; Albertson, B.; Lipsett, M.B. The new world primates as animal models of glucocorticoid resistance. Adv. Exp. Med. Biol., 1986, 196, 129-144.
13. Chrousos, G. P.; Loriaux, D. L.; Brandon, D.; Shull, J.; Renquist, D.; Hogan, W.; Tomita, M.; Lipsett, M.B. Adaptation of the mineralocorticoid target tissues to the high circulating cortisol and progesterone plasma levels in the squirrel monkey. Endocrinology, 1984, 115, 25-32.
14. Reynolds, P.D.; Pittler, S.J.; Scammell, J.G. Cloning and expression of the glucocorticoid receptor from the squirrel monkey (Saimiri boliviensis boliviensis), a glucocorticoid-resistant primate. J. Clin. Endocrinol. Metab., 1997, 82, 465-472.
15. Reynolds, P. D.; Ruan, Y.; Smith, D. F.; Scammell, J. G. (1999). Glucocorticoid resistance in the squirrel monkey is associated with overexpression of the immunophilin FKBP51. J. Clin. Endocrinol. Metab., 84, 663-669.
16. Denny, W.B.; Valentine, D.L.; Reynolds, P.D.; Smith, D.F.; Scammell, J.G. Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding. Endocrinology, 2000, 141, 4107-4113.
17. Schülke, J.P.; Wochnik, G.M.; Lang-Rollin, I.; Gassen, N.C.; Knapp, R.T.; Berning, B.; Yassouridis, A.; Rein, T. (2010). Differential impact of tetratricopeptide repeat proteins on the steroid hormone receptors. PLoS One, 5, e11717.
18. Wochnik, G.M.; Rüegg, J.; Abel, G.A.; Schmidt, U.; Holsboer, F.; Rein, T. FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J. Biol. Chem., 2005, 280, 4609-4616.
19. Riggs, D.L.; Roberts, P.J.; Chirillo, S.C.; Cheung-Flynn, J.; Prapapanich, V.; Ratajczak, T.; Gaber, R.; Picard, D.; Smith, D.F. (2003). The Hsp90-binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo. EMBO J., 2003, 22, 1158-1167.
20. Tatro, E.T.; Everall, I.P.; Kaul, M.; Achim, C.L. Modulation of glucocorticoid receptor nuclear translocation in neurons by immunophilins FKBP51 and FKBP52: implications for major depressive disorder. Brain Res., 2009, 1286, 1-12.
21. Galigniana, M.D.; Radanyi, C.; Renoir, J.M.; Housley, P.R.; Pratt, W. B. Evidence that the peptidylprolyl isomerase domain of the hsp90-binding immunophilin FKBP52 is involved in both dynein interaction and glucocorticoid receptor movement to the nucleus. J. Biol. Chem., 2001, 276, 14884-14889.
22. Gallo, L.I.; Ghini, A.A.; Pilipuk, G.P.; Galigniana, M.D. Differential recruitment of tetratricorpeptide repeat domain immunophilins to the mineralocorticoid receptor influences both heat-shock protein 90-dependent retrotransport and hormone-dependent transcriptional activity. Biochemistry, 2007, 46, 14044-14057.
23. Chambraud, B.; Belabes, H.; Fontaine-Lenoir, V.; Fellous, A.; Baulieu, E.E. The immunophilin FKBP52 specifically binds to tubulin and prevents microtubule formation. FASEB J., 2007, 21, 2787-2797.
24. Jinwal, U.K.; Koren, J.;Borysov, S.I.; Schmid, A.B.; Abisambra, J.F.; Blair, L.J.; Johnson, A.G.; Jones, J.R.; Shults, C.L.; O'Leary, J.C.;Jin, Y.; Buchner, J.; Cox, M.B.; Dickey, C.A. The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules. J. Neurosci: Official J. Soc. Neurosci., 2010, 30, 591-599.
25. Quinta, H. R.; Maschi, D.; Gomez-Sanchez, C.; Piwien-Pilipuk, G.; and Galigniana, M. D. (2010). Subcellular rearrangement of hsp90-binding immunophilins accompanies neuronal differentiation and neurite outgrowth. J. Neurochem., 2010, 115, 716-734.
26. Pei, H.; Li, L.; Fridley, B.L.; Jenkins, G.D.; Kalari, K.R.; Lingle, W.; Petersen, G.; Lou, Z.; Wang, L. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell, 2009, 16, 259-266.
27. Galigniana, M.D.; Erlejman, A.G.; Monte, M.; Gomez-Sanchez, C.; Piwien-Pilipuk, G. The hsp90-FKBP52 complex links the mineralocorticoid receptor to motor proteins and persists bound to the receptor in early nuclear events. Mol. Cell Biol., 2010, 30, 1285-1298.
28. Riggs, D.L.; Cox, M.B.; Tardif, H.L.; Hessling, M.; Buchner, J.; Smith, D.F. Noncatalytic role of the FKBP52 peptidyl-prolyl isomerase domain in the regulation of steroid hormone signaling. Mol. Cell Biol., 2007, 27, 8658-8669.
29. Barent, R.L.; Nair, S.C.; Carr, D.C.; Ruan, Y.; Rimerman, R.A.; Fulton, J.; Zhang, Y.; Smith, D.F. Analysis of FKBP51/FKBP52 chimeras and mutants for Hsp90 binding and association with progesterone receptor complexes. Mol. Endocrinol.. 1998, 12, 342-354.
30. Li, P.; Ding, Y.; Wu, B.; Shu, C.; Shen, B.; Rao, Z. Structure of the N-terminal domain of human FKBP52. Acta Crystallogr. D. Biol. Crystallogr., 2003, 59, 16-22.
31. Wu, B.; Li, P.; Liu, Y.; Lou, Z.; Ding, Y.; Shu, C.; Ye, S.; Bartlam, M.; Shen, B.; Rao, Z. 3D structure of human FK506-binding protein 52: implications for the assembly of the glucocorticoid receptor/ Hsp90/immunophilin heterocomplex. Proc. Natl. Acad.Sci.USA, 2004, 101, 8348-8353.
32. Sinars, C.R.; Cheung-Flynn, J.; Rimerman, R.A.; Scammell, J.G.; Smith, D.F.; Clardy, J. Structure of the large FK506-binding protein FKBP51, an Hsp90-binding protein and a component of steroid receptor complexes. Proc. Natl. Acad. Sci. USA, 2003, 100, 868-873.
33. Mustafi, S.M.; LeMaster, D.M.; Hernandez, G. Differential conformational dynamics in the closely homologous FK506-binding domains of FKBP51 and FKBP52. Biochem. J., 2041, 461, 115-123.
34. Denny, W.B.; Prapapanich, V.; Smith, D.F.; Scammell, J.G. Structure-function analysis of squirrel monkey FK506-binding protein 51, a potent inhibitor of glucocorticoid receptor activity. Endocrinology, 2005, 146, 3194-3201.
35. Reynolds, P.D.; Roveda, K. P.; Tucker, J.A.; Moore, C.M.; Valentine, D.L.; Scammell, J.G. (1-1-1998). Glucocorticoid-resistant Blymphoblast cell line derived from the Bolivian squirrel monkey (Saimiri boliviensis boliviensis). Lab. Anim. Sci., 48, 364-370.
36. Baughman, G.; Wiederrecht, G.J.; Chang, F.; Martin, M.M.; Bourgeois, S. Tissue distribution and abundance of human FKBP51, and FK506-binding protein that can mediate calcineurin inhibition. Biochem. Biophys. Res. Communi., 1997, 232, 437-443.
37. Harrigan, M.T.; Baughman, G.; Campbell, N.F.; Bourgeois, S. (1989). Isolation and characterization of glucocorticoid-and cyclic AMP-induced genes in T lymphocytes. Mol. Cell Biol., 9, 3438-3446.
38. Scharf, S.H.; Liebl, C.; Binder, E.B.; Schmidt, M.V.; Muller, M.B. Expression and regulation of the Fkbp5 gene in the adult mouse brain. PLoS One, 2011, 6, e16883.
39. Woodruff, P.G.; Boushey, H.A.; Dolganov, G.M.; Barker, C.S.; Yang, Y.H.; Donnelly, S.; Ellwanger, A.; Sidhu, S.S.; Dao-Pick, T. P.; Pantoja, C.; Erle, D.J.; Yamamoto, K.R.; Fahy, J.V. Genomewide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc. Natl. Acad. Sci. USA, 2007, 104, 15858-15863.
40. Lee, R.S.; Tamashiro, K.L.; Yang, X.; Purcell, R.H.; Harvey, A.; Willour, V.L.; Huo, Y.; Rongione, M.; W,G.S. Potash, J.B. Chronic corticosterone exposure increases expression and decreases deoxyribonucleic acid methylation of Fkbp5 in mice. Endocrinology, 2010, 151, 4332-4343.
41. Hubler, T.R. Scammell, J.G. Intronic hormone response elements mediate regulation of FKBP5 by progestins and glucocorticoids. Cell Stress Chaperones, 2004, 9, 243-252.
42. Paakinaho, V.; Makkonen, H.; Jaaskelainen, T.; Palvimo, J.J. Glucocorticoid receptor activates poised FKBP51 locus through long-distance interactions. Mol. Endocrinol., 2010, 24, 511-525.
43. Klengel, T.; Mehta, D.; Anacker, C.; Rex-Haffner, M.; Pruessner, J.C.; Pariante, C.M.; Pace, T.W.; Mercer, K.B.; Mayberg, H.S.; Bradley, B.; Nemeroff, C.B.; Holsboer, F.; Heim, C. M.; Ressler, K.J.; Rein, T.; Binder, E.B. Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat. Neurosci., 2013, 16, 33-41.
44. Jääskeläinen, T.; Makkonen, H.; Palvimo, J.J. Steroid upregulation of FKBP51 and its role in hormone signaling. Curr. Opin. Pharmacol., 2011, 11, 326-331.
45. Makkonen, H.; Kauhanen, M.; Paakinaho, V.; Jaaskelainen, T.; Palvimo, J. J. (2009). Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers. Nucleic Acids Res., 37, 4135-4148.
46. Hubler, T. R.; Denny, W. B.; Valentine, D. L.; Cheung-Flynn, J.; Smith, D. F.; Scammell, J. G. (2003). The FK506-Binding Immunophilin FKBP51 Is Transcriptionally Regulated by Progestin and Attenuates Progestin Responsiveness. Endocrinology, 144, 2380-2387.
47. Magee, J.A.; Chang, L.W.; Stormo, G.D.; Milbrandt, J. Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element. Endocrinology, 2006, 147, 590-598.
48. Velasco, A.M.; Gillis, K.A.; Li, Y.; Brown, E.L.; Sadler, T.M.; Achilleos, M.; Greenberger, L.M.; Frost, P.; Bai, W.; Zhang, Y. Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology, 2004, 145, 3913-3924.
49. Galat, A. A note on clustering the functionally-related paralogues and orthologues of proteins: a case of the FK506-binding proteins (FKBPs). Comput. Biol. Chem., 2004, 28, 129-140.
50. Cioffi, D.L.; Hubler, T.R.; Scammell, J.G. Organization and function of the FKBP52 and FKBP51 genes. Curr. Opin. Pharmacol., 2011, 11, 308-313.
51. Vermeer, H.; Hendriks-Stegeman, B.I.; van der Burg, B.; Van Buul-Offers, S.C.; Jansen, M. Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability. J. Clin. Endocrinol. Metab., 2003, 88, 277-284.
52. Klengel, T. Binder, E.B. Allele-specific epigenetic modification: a molecular mechanism for gene-environment interactions in stressrelated psychiatric disorders? Epigenomics, 2013, 5, 109-112.
53. Polman, J.A.; Hunter, R.G.; Speksnijder, N.; van den Oever, J.M.; Korobko, O.B.; McEwen, B.S.; De Kloet, E.R.; Datson, N.A. Glucocorticoids modulate the mTOR pathway in the hippocampus: differential effects depending on stress history. Endocrinology, 2012, 153, 4317-4327.
54. Datson, N.A.; van den Oever, J.M.; Korobko, O.B.; Magarinos, A. M.; De Kloet, E.R.; McEwen, B.S. Previous history of chronic stress changes the transcriptional response to glucocorticoid challenge in the dentate gyrus region of the male rat hippocampus. Endocrinology, 2013, 154, 3261-3272.
55. Cheung-Flynn, J.; Prapapanich, V.; Cox, M. B.; Riggs, D. L.; Suarez-Quian, C.; Smith, D.F. Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Mol. Endocrinol., 2005, 19, 1654-1666.
56. Yong, W.; Yang, Z.; Periyasamy, S.; Chen, H.; Yucel, S.; Li, W.; Lin, L.Y.; Wolf, I.M.; Cohn, M.J.; Baskin, L.S.; Sanchez, E.R.; Shou, W. Essential role for Co-chaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology. J. Biol. Chem., 2007, 282, 5026-5036.
57. Tranguch, S.; Cheung-Flynn, J.; Daikoku, T.; Prapapanich, V.; Cox, M.B.; Xie, H.; Wang, H.; Das, S.K.; Smith, D.F.; Dey, S.K. Cochaperone immunophilin FKBP52 is critical to uterine receptivity for embryo implantation. Proc. Natl. Acad. Sci. USA, 2005, 102, 14326-14331.
58. Hoeijmakers, L.; Harbich, D.; Schmid, B.; Lucassen, P.J.; Wagner, K.V.; Schmidt, M.V.; Hartmann, J. Depletion of FKBP51 in female mice shapes HPA axis activity. PLoS One, 2014, 9, e95796.
59. Sanchez, E.R. Chaperoning steroidal physiology: lessons from mouse genetic models of Hsp90 and its cochaperones. Biochim. Biophys. Acta., 2012, 1823, 722-729.
60. Febbo, P.G.; Lowenberg, M.; Thorner, A.R.; Brown, M.; Loda, M.; Golub, T.R. (2005). Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. J. Urol., 2005, 173, 1772-1777.
61. Ni, L.; Yang, C.S.; Gioeli, D.; Frierson, H.; Toft, D.O.; Paschal, B.M. FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells. Mol. Cell Biol., 2010, 30, 1243-1253.
62. Periyasamy, S.; Hinds, T.; Jr.; Shemshedini, L.; Shou, W.; Sanchez, E.R. FKBP51 and Cyp40 are positive regulators of androgendependent prostate cancer cell growth and the targets of FK506 and cyclosporin A. Oncogene, 2010, 29, 1691-1701.
63. Touma, C.; Gassen, N.C.; Herrmann, L.; Cheung-Flynn, J.; Bull, D. R.; Ionescu, I.A.; Heinzmann, J.M.; Knapman, A.; Siebertz, A.; Depping, A.M.; Hartmann, J.; Hausch, F.; Schmidt, M.V.; Holsboer, F.; Ising, M.; Cox, M.B.; Schmidt, U.; Rein, T. FK506 binding protein 5 shapes stress responsiveness: modulation of neuroendocrine reactivity and coping behavior. Biol. Psychiatry, 2011, 70, 928-936.
64. Schmidt, U.; Buell, D.R.; Ionescu, I.A.; Gassen, N.C.; Holsboer, F.; Cox, M.B.; Novak, B.; Huber, C.; Hartmann, J.; Schmidt, M.V.; Touma, C.; Rein, T.; Herrmann, L. A role for synapsin in FKBP51 modulation of stress responsiveness: convergent evidence from animal and human studies. Psychoneuroendocrinology, 2015, 52, 43-58.
65. Hartmann, J.; Wagner, K.V.; Liebl, C.; Scharf, S.H.; Wang, X.D.; Wolf, M.; Hausch, F.; Rein, T.; Schmidt, U.; Touma, C.; Cheung-Flynn, J.; Cox, M.B.; Smith, D.F.; Holsboer, F.; Muller, M.B.; Schmidt, M.V. The involvement of FK506-binding protein 51 (FKBP5) in the behavioral and neuroendocrine effects of chronic social defeat stress. Neuropharmacology, 2012, 62, 332-339.
66. Buckley, T.M. Schatzberg, A.F. On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J. Clin. Endocrinol. Metab., 2005, 90, 3106-3114.
67. Albu, S.; Romanowski, C.P.; Letizia, Curzi M.; Jakubcakova, V.; Flachskamm, C.; Gassen, N. C.; Hartmann, J.; Schmidt, M. V.; Schmidt, U.; Rein, T.; Holsboer, F.; Hausch, F.; Paez-Pereda, M.; Kimura, M. Deficiency of FK506-binding protein (FKBP) 51 alters sleep architecture and recovery sleep responses to stress in mice. J. Sleep Res., 2014, 23, 176-185.
68. O'Leary, J.C.;Dharia, S.; Blair, L.J.; Brady, S.; Johnson, A.G.; Peters, M.; Cheung-Flynn, J.; Cox, M.B.; de Erausquin G.; Weeber, E.J.; Jinwal, U.K.; Dickey, C.A. A new anti-depressive strategy for the elderly: ablation of FKBP5/FKBP51. PLoS One, 2011, 6, e24840.
69. Sabbagh, J.J.; O'Leary, J.C.;Blair, L.J.; Klengel, T.; Nordhues, B.A.; Fontaine, S.N.; Binder, E.B.; Dickey, C.A. Age-associated epigenetic upregulation of the FKBP5 gene selectively impairs stress resiliency. PLoS One, 2014, 9, e107241.
70. Kollmannsberger, L.K.; Gassen, N.C.; Bultmann, A.; Hartmann, J.; Weber, P.; Schmidt, M.V.; Rein, T. Increased glyoxalase-1 levels in Fkbp5 knockout mice caused by glyoxalase-1 gene duplication. G3. Bethesda, 3, 2013, 1311-1313.
71. Thornalley, P.J. Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems--role in ageing and disease. Drug Metabol. Drug Interact., 2008, 23, 125-150.
72. Distler, M.G. Palmer, A.A. (2012). Role of Glyoxalase 1 (Glo1) and methylglyoxal (MG) in behavior: recent advances and mechanistic insights. Front Genet. 3, 250.
73. Distler, M.G.; Plant, L.D.; Sokoloff, G.; Hawk, A.J.; Aneas, I.; Wuenschell, G.E.; Termini, J.; Meredith, S.C.; Nobrega, M.A.; Palmer, A.A. (2012). Glyoxalase 1 increases anxiety by reducing GABAA receptor agonist methylglyoxal. J. Clin. Invest., 2012, 122, 2306-2315.
74. Attwood, B.K.; Bourgognon, J.M.; Patel, S.; Mucha, M.; Schiavon, E.; Skrzypiec, A.E.; Young, K.W.; Shiosaka, S.; Korostynski, M.; Piechota, M.; Przewlocki, R.; Pawlak, R. Neuropsin cleaves EphB2 in the amygdala to control anxiety. Nature, 2011, 473, 372-375.
75. Yang, L.; Isoda, F.; Yen, K.; Kleopoulos, S.P.; Janssen, W.; Fan, X.; Mastaitis, J.; Dunn-Meynell, A.; Levin, B.; McCrimmon, R.; Sherwin, R.; Musatov, S.; Mobbs, C.V. Hypothalamic Fkbp51 is induced by fasting, and elevated hypothalamic expression promotes obese phenotypes. Am. J. Physiol. Endocrinol. Metab., 2012, 302, E987-E991.
76. Balsevich, G.; Uribe, A.; Wagner, K.V.; Hartmann, J.; Santarelli, S.; Labermaier, C.; Schmidt, M.V. Interplay between diet-induced obesity and chronic stress in mice: potential role of FKBP51. J. Endocrinol., 2014, 222, 15-26.
77. Faith, M.S.; Butryn, M.; Wadden, T.A.; Fabricatore, A.; Nguyen, A.M.; Heymsfield, S. B. Evidence for prospective associations among depression and obesity in population-based studies. Obes. Rev., 2011, 12, e438-e453.
78. De Kloet, E.R.; Joels, M.; Holsboer, F. Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci., 2005, 6, 463-475.
79. Holsboer, F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology, 2000, 23, 477-501.
80. Pepin, M.C.; Govindan, M.V.; Barden, N. Increased glucocorticoid receptor gene promoter activity after antidepressant treatment. Mol. Pharmacol., 1992, 41, 1016-1022.
81. Pepin, M.C.; Pothier, F.; Barden, N. Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene. Nature, 1992, 355, 725-728.
82. Montkowski, A.; Barden, N.; Wotjak, C.; Stec, I.; Ganster, J.; Meaney, M.; Engelmann, M.; Reul, J.M.; Landgraf, R.; Holsboer, F. Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function 55. J. Neuroendocrinol., 1995, 7, 841-845.
83. Tronche, F.; Kellendonk, C.; Kretz, O.; Gass, P.; Anlag, K.; Orban, P.C.; Bock, R.; Klein, R.; Schütz, G. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat. Genet., 1999, 23, 99-103.
84. Reichardt, H.M.; Umland, T.; Bauer, A.; Kretz, O.; Schutz, G. Mice with an Increased Glucocorticoid Receptor Gene Dosage Show Enhanced Resistance to Stress and Endotoxic Shock 1096. Mol. Cell Biol., 2000, 20, 9009-9017.
85. Ridder, S.; Chourbaji, S.; Hellweg, R.; Urani, A.; Zacher, C.; Schmid, W.; Zink, M.; Hortnagl, H.; Flor, H.; Henn, F.A.; Schutz, G.; Gass, P. Mice with genetically altered glucocorticoid receptor expression show altered sensitivity for stress-induced depressive reactions. J. Neurosci: Official J.the Soc. Neurosci., 2005, 25, 6243-6250.
86. Boyle, M.P.; Brewer, J.A.; Funatsu, M.; Wozniak, D.F.; Tsien, J. Z.; Izumi, Y.; Muglia, L.J. Acquired deficit of forebrain glucocorticoid receptor produces depression-like changes in adrenal axis regulation and behavior. Proc. Natl. Acad Sci. USA, 2005, 102, 473-478.
87. Wei, Q.; Lu, X. Y.; Liu, L.; Schafer, G.; Shieh, K. R.; Burke, S.; Robinson, T. E.; Watson, S. J.; Seasholtz, A. F.; Akil, H. (2004). Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability. Proc Natl Acad Sci USA, 101, 11851-11856.
88. Binder, E.B.; Salyakina, D.; Lichtner, P.; Wochnik, G.M.; Ising, M.; Putz, B.; Papiol, S.; Seaman, S.; Lucae, S.; Kohli, M.A.; Nickel, T.; Kunzel, H. E.; Fuchs, B.; Majer, M.; Pfennig, A.; Kern, N.; Brunner, J.; Modell, S.; Baghai, T.; Deiml, T.; Zill, P.; Bondy, B.; Rupprecht, R.; Messer, T.; Kohnlein, O.; Dabitz, H.; Bruckl, T.; Muller, N.; Pfister, H.; Lieb, R.; Mueller, J. C.; Lohmussaar, E.; Strom, T. M.; Bettecken, T.; Meitinger, T.; Uhr, M.; Rein, T.; Holsboer, F.; Muller-Myhsok, B. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Geneti., 2004, 36, 1319-1325.
89. Mehta, D.; Gonik, M.; Klengel, T.; Rex-Haffner, M.; Menke, A.; Rubel, J.; Mercer, K.B.; Putz, B.; Bradley, B.; Holsboer, F.; Ressler, K.J.; Muller-Myhsok, B.; Binder, E.B. Using polymorphisms in FKBP5 to define biologically distinct subtypes of posttraumatic stress disorder: evidence from endocrine and gene expression studies. Arch. Gen. Psychiatry, 2011, 68, 901-910.
90. Paquette, A.G.; Lester, B.M.; Koestler, D.C.; Lesseur, C.; Armstrong, D.A.; Marsit, C.J. Placental FKBP5 genetic and epigenetic variation is associated with infant neurobehavioral outcomes in the RICHS cohort. PLoS One, 2014, 9, e104913.
91. Sarapas, C.; Cai, G.; Bierer, L.M.; Golier, J.A.; Galea, S.; Ising, M.; Rein, T.; Schmeidler, J.; Muller-Myhsok, B.; Uhr, M.; Holsboer, F.; Buxbaum, J.D.; Yehuda, R. Genetic markers for PTSD risk and resilience among survivors of the World Trade Center attacks. Dis. Markers, 2011, 30, 101-110.
92. Fujii, T.; Hori, H.; Ota, M.; Hattori, K.; Teraishi, T.; Sasayama, D.; Yamamoto, N.; Higuchi, T.; Kunugi, H. Effect of the common functional FKBP5 variant (rs1360780) on the hypothalamicpituitary-adrenal axis and peripheral blood gene expression. Psychoneuroendocrinology, 2014, 42, 89-97.
93. Ising, M.; Depping, A.M.; Siebertz, A.; Lucae, S.; Unschuld, P. G.; Kloiber, S.; Horstmann, S.; Uhr, M.; Muller-Myhsok, B.; Holsboer, F. Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. Eur. J. Neurosci., 2008, 28, 389-398.
94. Mahon, P.B.; Zandi, P.P.; Potash, J.B.; Nestadt, G.; Wand, G.S. Genetic association of FKBP5 and CRHR1 with cortisol response to acute psychosocial stress in healthy adults. Psychopharmacology (Berl), 2013, 227, 231-241.
95. Shibuya, N.; Suzuki, A.; Sadahiro, R.; Kamata, M.; Matsumoto, Y.; Goto, K.; Hozumi, Y.; Otani, K. Association study between a functional polymorphism of FK506-binding protein 51 (FKBP5) gene and personality traits in healthy subjects. Neurosci. Lett., 2010, 485, 194-197.
96. Fani, N.; Gutman, D.; Tone, E.B.; Almli, L.; Mercer, K.B.; Davis, J.; Glover, E.; Jovanovic, T.; Bradley, B.; Dinov, I.D.; Zamanyan, A.; Toga, A.W.; Binder, E.B.; Ressler, K.J. FKBP5 and attention bias for threat: associations with hippocampal function and shape. JAMA Psychiatry, 2013, 70, 392-400.
97. Fani, N.; King, T.Z.; Reiser, E.; Binder, E.B.; Jovanovic, T.; Bradley, B.; Ressler, K.J. FKBP5 genotype and structural integrity of the posterior cingulum. Neuropsychopharmacology, 2014, 39, 1206-1213.
98. Fujii, T.; Ota, M.; Hori, H.; Hattori, K.; Teraishi, T.; Sasayama, D.; Higuchi, T.; Kunugi, H. Association between the common functional FKBP5 variant (rs1360780) and brain structure in a nonclinical population. J. Psychiatr. Res., 2014, 58, 96-101.
99. Levy-Gigi, E.; Szabó, C.; Kelemen, O.; Kéri, S. Association among clinical response, hippocampal volume, and FKBP5 gene expression in individuals with posttraumatic stress disorder receiving cognitive behavioral therapy. Biol. Psychiatry, 2013, 74, 793-800.
100. White, M.G.; Bogdan, R.; Fisher, P.M.; Muñoz, K.E.; Williamson, D.E.; Hariri, A.R. FKBP5 and emotional neglect interact to predict individual differences in amygdala reactivity. Genes Brain Behav., 2012, 11, 869-878.
101. Buchmann, A.F.; Holz, N.; Boecker, R.; Blomeyer, D.; Rietschel, M.; Witt, S.H.; Schmidt, M.H.; Esser, G.; Banaschewski, T.; Brandeis, D.; Zimmermann, U.S.; Laucht, M. Moderating role of FKBP5 genotype in the impact of childhood adversity on cortisol stress response during adulthood. Eur. Neuropsychopharmacol., 2014, 24, 837-845.
102. Pagliaccio, D.; Luby, J.L.; Bogdan, R.; Agrawal, A.; Gaffrey, M. S.; Belden, A.C.; Botteron, K.N.; Harms, M.P.; Barch, D.M. Stress-system genes and life stress predict cortisol levels and amygdala and hippocampal volumes in children. Neuropsychopharmacology, 2014, 39, 1245-1253.
103. Roy, A.; Gorodetsky, E.; Yuan, Q.; Goldman, D.; Enoch, M.A. Interaction of FKBP5, a stress-related gene, with childhood trauma increases the risk for attempting suicide. Neuropsychopharmacology, 2010, 35, 1674-1683.
104. Luijk, M.P.; Velders, F.P.; Tharner, A.; van Ijzendoorn, M.H.; Bakermans-Kranenburg, M. J.; Jaddoe, V. W.; Hofman, A.; Verhulst, F.C.; Tiemeier, H. FKBP5 and resistant attachment predict cortisol reactivity in infants: gene-environment interaction. Psychoneuroendocrinology, 2010, 35, 1454-1461.
105. Daskalakis, N.P.; Lehrner, A.; Yehuda, R. Endocrine aspects of post-traumatic stress disorder and implications for diagnosis and treatment. Endocrinol. Metab. Clin. North Am., 2013, 42, 503-513.
106. Yehuda, R.; Cai, G.; Golier, J.A.; Sarapas, C.; Galea, S.; Ising, M.; Rein, T.; Schmeidler, J.; Muller-Myhsok, B.; Holsboer, F.; Buxbaum, J.D. Gene Expression Patterns Associated with Posttraumatic Stress Disorder Following Exposure to the World Trade Center Attacks. Biol. Psychiatry, 2009, 66, 708-711.
107. van Zuiden, M.; Geuze, E.; Willemen, H.L.; Vermetten, E.; Maas, M.; Amarouchi, K.; Kavelaars, A.; Heijnen, C.J. Glucocorticoid receptor pathway components predict posttraumatic stress disorder symptom development: a prospective study. Biol. Psychiatry, 2012, 71, 309-316.
108. Segman, R.H.; Shefi, N.; Goltser-Dubner, T.; Friedman, N.; Kaminski, N.; Shalev, A.Y. Peripheral blood mononuclear cell gene expression profiles identify emergent post-traumatic stress disorder among trauma survivors 2508. Mol. Psychiatry, 2005, 10, 500-13, 425.
109. Szabó, C.; Kelemen, O.; Keri, S. Changes in FKBP5 expression and memory functions during cognitive-behavioral therapy in posttraumatic stress disorder: a preliminary study. Neurosci. Lett., 2014, 569, 116-120.
110. Boscarino, J.A.; Erlich, P.M.; Hoffman, S.N.; Zhang, X. Higher FKBP5, COMT, CHRNA5, and CRHR1 allele burdens are associated with PTSD and interact with trauma exposure: implications for neuropsychiatric research and treatment. Neuropsychiatr. Dis. Treat., 2012, 8, 131-139.
111. Boscarino, J.A.; Erlich, P.M.; Hoffman, S.N.; Rukstalis, M.; Stewart, W.F. Association of FKBP5, COMT and CHRNA5 polymorphisms with PTSD among outpatients at risk for PTSD. Psychiatry Res., 2011, 188, 173-174.
112. Boscarino, J. A.; Kirchner, H. L.; Hoffman, S. N.; Erlich, P. M. Predicting PTSD using the New York Risk Score with genotype data: potential clinical and research opportunities. Neuropsychiatr. Dis. Treat., 2013, 9, 517-527.
113. Schmidt, U.; Willmund, G.D.; Holsboer, F.; Wotjak, C.T.; Gallinat, J.; Kowalski, J.T.; Zimmermann, P. Searching for non-genetic molecular and imaging PTSD risk and resilience markers: Systematic review of literature and design of the German Armed Forces PTSD biomarker study. Psychoneuroendocrinology, 2014
114. Wilker, S.; Pfeiffer, A.; Kolassa, S.; Elbert, T.; Lingenfelder, B.; Ovuga, E.; Papassotiropoulos, A.; de Quervain D.; Kolassa, I. T. The role of FKBP5 genotype in moderating long-term effectiveness of exposure-based psychotherapy for posttraumatic stress disorder. Transl. Psychiatry, 2014, 4, e403.
115. Yehuda, R.; Daskalakis, N.P.; Desarnaud, F.; Makotkine, I.; Lehrner, A.L.; Koch, E.; Flory, J.D.; Buxbaum, J.D.; Meaney, M. J.; Bierer, L.M. Epigenetic Biomarkers as Predictors and Correlates of Symptom Improvement Following Psychotherapy in Combat Veterans with PTSD. Front. Psychiatry, 2013, 4, 118.
116. Binder, E.B.; Bradley, R.G.; Liu, W.; Epstein, M.P.; Deveau, T.C.; Mercer, K.B.; Tang, Y.; Gillespie, C.F.; Heim, C.M.; Nemeroff, C. B.; Schwartz, A.C.; Cubells, J.F.; Ressler, K.J. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA, 2008, 299, 1291-1305.
117. Xie, P.; Kranzler, H.R.; Poling, J.; Stein, M.B.; Anton, R.F.; Farrer, L.A.; Gelernter, J. Interaction of FKBP5 with childhood adversity on risk for post-traumatic stress disorder. Neuropsychopharmacology, 2010, 35, 1684-1692.
118. Bevilacqua, L.; Carli, V.; Sarchiapone, M.; George, D.K.; Goldman, D.; Roy, A.; Enoch, M.A. Interaction between FKBP5 and childhood trauma and risk of aggressive behavior. Arch. Gen. Psychiatry, 2012, 69, 62-70.
119. Appel, K.; Schwahn, C.; Mahler, J.; Schulz, A.; Spitzer, C.; Fenske, K.; Stender, J.; Barnow, S.; John, U.; Teumer, A.; Biffar, R.; Nauck, M.; Volzke, H.; Freyberger, H.J.; Grabe, H.J. Moderation of adult depression by a polymorphism in the FKBP5 gene and childhood physical abuse in the general population. Neuropsychopharmacology, 2011, 36, 1982-1991.
120. Zimmermann, P.; Brückl, T.; Nocon, A.; Pfister, H.; Binder, E. B.; Uhr, M.; Lieb, R.; Moffitt, T.E.; Caspi, A.; Holsboer, F.; Ising, M. Interaction of variants in the FKBP5 gene and adverse life events in predicting the first depression onset: results from a ten-year prospective community study. Am. J. Psychiatry, 2011, 168, 1107-1116.
121. Lavebratt, C.; Aberg, E.; Sjoholm, L.K.; Forsell, Y. Variations in FKBP5 and BDNF genes are suggestively associated with depression in a Swedish population-based cohort. J. Affect. Disord.. 2010, 125, 249-255.
122. Lekman, M.; Laje, G.; Charney, D.; Rush, A.J.; Wilson, A.F.; Sorant, A.J.; Lipsky, R.; Wisniewski, S.R.; Manji, H.; McMahon, F.J.; Paddock, S. The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol. Psychiatry, 2008, 63, 1103-1110.
123. Szczepankiewicz, A.; Leszczynska-Rodziewicz, A.; Pawlak, J.; Narozna, B.; Rajewska-Rager, A.; Wilkosc, M.; Zaremba, D.; Maciukiewicz, M.; Twarowska-Hauser, J. FKBP5 polymorphism is associated with major depression but not with bipolar disorder. J. Affect. Disord., 2014, 164, 33-37.
124. Tatro, E.T.; Everall, I.P.; Masliah, E.; Hult, B.J.; Lucero, G.; Chana, G.; Soontornniyomkij, V.; Achim, C.L. Differential expression of immunophilins FKBP51 and FKBP52 in the frontal cortex of HIV-infected patients with major depressive disorder. J. Neuroimmune. Pharmacol., 2009, 4, 218-226.
125. Zobel, A.; Schuhmacher, A.; Jessen, F.; Hofels, S.; von Widdern O.; Metten, M.; Pfeiffer, U.; Hanses, C.; Becker, T.; Rietschel, M.; Scheef, L.; Block, W.; Schild, H.H.; Maier, W.; Schwab, S. G. (2010). DNA sequence variants of the FKBP5 gene are associated with unipolar depression. Int. J. Neuropsychopharmacol. 13, 649-660.
126. Velders, F.P.; Kuningas, M.; Kumari, M.; Dekker, M.J.; Uitterlinden, A.G.; Kirschbaum, C.; Hek, K.; Hofman, A.; Verhulst, F.C.; Kivimaki, M.; Van Duijn, C.M.; Walker, B.R.; Tiemeier, H. Genetics of cortisol secretion and depressive symptoms: A candidate gene and genome wide association approach. Psychoneuroendocrinology, 2011, 36, 1053-1061
127. Suzuki, A.; Matsumoto, Y.; Sadahiro, R.; Enokido, M.; Goto, K.; Otani, K. Relationship of the FKBP5 C/T polymorphism with dysfunctional attitudes predisposing to depression. Compr. Psychiatry, 2014, 55, 1422-1425.
128. Lukic, I.; Mitic, M.; Soldatovic, I.; Jovicic, M.; Maric, N.; Radulovic, J.; Adzic, M. Accumulation of Cytoplasmic Glucocorticoid Receptor Is Related to Elevation of FKBP5 in Lymphocytes of Depressed Patients. J. Mol. Neurosci., 2014.
129. Arlt, S.; Demiralay, C.; Tharun, B.; Geisel, O.; Storm, N.; Eichenlaub, M.; Lehmbeck, J.T.; Wiedemann, K.; Leuenberger, B.; Jahn, H. Genetic risk factors for depression in Alzheimer`s disease patients. Curr. Alzheimer Res., 2013, 10, 72-81.
130. Shinozaki, G.; Jowsey, S.; Amer, H.; Biernacka, J.; Colby, C.; Walker, D.; Black, J.; Rundell, J.; Stegall, M.; Mrazek, D. A. (2011). Relationship between FKBP5 polymorphisms and depression symptoms among kidney transplant recipients. Depress. Anxiety, 28, 1111-1118.
131. Kang, J. I.; Chung, H. C.; Jeung, H. C.; Kim, S. J.; An, S. K.; Namkoong, K. (2012). FKBP5 polymorphisms as vulnerability to anxiety and depression in patients with advanced gastric cancer: a controlled and prospective study. Psychoneuroendocrinology, 37, 1569-1576.
132. Minelli, A.; Maffioletti, E.; Cloninger, C. R.; Magri, C.; Sartori, R.; Bortolomasi, M.; Congiu, C.; Bignotti, S.; Segala, M.; Giacopuzzi, M.; Gennarelli, M. Role of allelic variants of FK506-binding protein 51 (FKBP5) gene in the development of anxiety disorders. Depress. Anxiety, 2013, 30, 1170-1176.
133. Katz, E.R.; Stowe, Z.N.; Newport, D.J.; Kelley, M.E.; Pace, T.W.; Cubells, J.F.; Binder, E.B. Regulation of mRNA expression encoding chaperone and co-chaperone proteins of the glucocorticoid receptor in peripheral blood: association with depressive symptoms during pregnancy. Psychol. Med., 2012, 42, 943-956.
134. Menke, A.; Klengel, T.; Rubel, J.; Bruckl, T.; Pfister, H.; Lucae, S.; Uhr, M.; Holsboer, F.; Binder, E.B. Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. Genes Brain Behav., 2013, 12, 289-296.
135. Horstmann, S.; Lucae, S.; Menke, A.; Hennings, J. M.; Ising, M.; Roeske, D.; Muller-Myhsok, B.; Holsboer, F.; Binder, E. B. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology, 2010, 35, 727-740.
136. Kirchheiner, J.; Lorch, R.; Lebedeva, E.; Seeringer, A.; Roots, I.; Sasse, J.; Brockmoller, J. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics, 2008, 9, 841-846.
137. Ellsworth, K.A.; Moon, I.; Eckloff, B.W.; Fridley, B.L.; Jenkins, G. D.; Batzler, A.; Biernacka, J.M.; Abo, R.; Brisbin, A.; Ji, Y.; Hebbring, S.; Wieben, E.D.; Mrazek, D.A.; Weinshilboum, R.M.; Wang, L. FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet. Genomics, 2013, 23, 156-166.
138. Laje, G.; Perlis, R.H.; Rush, A.J.; McMahon, F.J. Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr. Serv., 2009, 60, 1446-1457.
139. Zou, Y.F.; Wang, F.; Feng, X.L.; Li, W.F.; Tao, J.H.; Pan, F.M.; Huang, F.; Su, H. Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders. Neurosci. Lett., 2010, 484, 56-61.
140. Cattaneo, A.; Gennarelli, M.; Uher, R.; Breen, G.; Farmer, A.; Aitchison, K.J.; Craig, I.W.; Anacker, C.; Zunsztain, P.A.; McGuffin, P.; Pariante, C.M. Cidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology, 2013, 38, 377-385.
141. Brent, D.; Melhem, N.; Ferrell, R.; Emslie, G.; Wagner, K.D.; Ryan, N.; Vitiello, B.; Birmaher, B.; Mayes, T.; Zelazny, J.; Onorato, M.; Devlin, B.; Clarke, G.; Debar, L.; Keller, M. Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am. J. Psychiatry, 2010, 167, 190-197.
142. Papiol, S.; Arias, B.; Gastó, C.; Gutiérrez, B.; Catalán, R.; Fañanás, L. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J. Affect. Disord., 2007, 104, 83-90.
143. Sarginson, J.E.; Lazzeroni, L.C.; Ryan, H.S.; Schatzberg, A.F.; Murphy, G.M.; FKBP5 polymorphisms and antidepressant response in geriatric depression. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2010, 153B, 554-560.
144. Tsai, S.J.; Hong, C.J.; Chen, T.J.; Yu, Y.W. Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment 26. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2007, 144B, 1097-1098.
145. Niitsu, T.; Fabbri, C.; Bentini, F.; Serretti, A. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2013, 45, 183-194.
146. Ceulemans, S.; De Zutter S.; Heyrman, L.; Norrback, K.F.; Nordin, A.; Nilsson, L.G.; Adolfsson, R.; Del-Favero, J.; Claes, S. Evidence for the involvement of the glucocorticoid receptor gene in bipolar disorder in an isolated northern Swedish population. Bipolar. Disord., 2011, 13, 614-623.
147. Leszczyñska-Rodziewicz, A.; Szczepankiewicz, A.; Narozna, B.; Skibiñska, M.; Pawlak, J.; Dmitrzak-Weglarz, M.; Hauser, J. Possible association between haplotypes of the FKBP5 gene and suicidal bipolar disorder, but not with melancholic depression and psychotic features, in the course of bipolar disorder. Neuropsychiatr. Dis. Treat., 2014, 10, 243-248.
148. Willour, V.L.; Chen, H.; Toolan, J.; Belmonte, P.; Cutler, D.J.; Goes, F.S.; Zandi, P.P.; Lee, R.S.; Mackinnon, D.F.; Mondimore, F.M.; Schweizer, B.; Depaulo, J.R.; Jr.; Gershon, E.S.; McMahon, F.J.; Potash, J.B. Family-based association of FKBP5 in bipolar disorder. Mol. Psychiatry, 2008, 14, 261-268.
149. Schmidt, U.; Wochnik, G.M.; Rosenhagen, M.C.; Young, J.C.; Hartl, F.U.; Rein, T. Essential role of the unusual DNA binding motif of BAG-1 for inhibition of the glucocorticoid receptor. J. Biol.l Chem., 2003, 278, 4926-4931.
150. Schmidt, U.; Holsboer, F.; Rein, T. Role of the hsp70 cochaperone BAG1 in glucocorticoid receptor function and stress-related diseases. Proc. Natl. Acad. Sci.USA, 2008, 105, E101.
151. Sinclair, D.; Fillman, S.G.; Webster, M.J.; Weickert, C.S. Dysregulation of glucocorticoid receptor co-factors FKBP5, BAG1 and PTGES3 in prefrontal cortex in psychotic illness. Sci. Rep., 2013, 3, 3539.
152. Seifuddin, F.; Pirooznia, M.; Judy, J.T.; Goes, F.S.; Potash, J.B.; Zandi, P.P. Systematic review of genome-wide gene expression studies of bipolar disorder. BMC Psychiatry, 2013, 13, 213.
153. Fries, G.R.; Moreno, M.P.V.; Gubert, C.; Santos, B.T.M.Q.; Sartori, J.; Eisele, B.; Ferrari, P.; Fijtman, A.; Rüegg, J.; Gassen, N. C.; Kapczinski, F.; Rein, T.; Kauer-Sant'Anna, M. Hypothalamicpituitary-adrenal axis dysfunction and illness progression in bipolar disorder. Int. J. Neuropsychopharmacology, 2014.
154. Daban, C.; Vieta, E.; Mackin, P.; Young, A.H. Hypothalamicpituitary-adrenal axis and bipolar disorder. Psychiatr. Clin. North Am., 2005, 28, 469-480.
155. Collip, D.; Myin-Germeys, I.; Wichers, M.; Jacobs, N.; Derom, C.; Thiery, E.; Lataster, T.; Simons, C.; Delespaul, P.; Marcelis, M.; van Os J.; van Winkel R. FKBP5 as a possible moderator of the psychosis-inducing effects of childhood trauma. Br. J. Psychiatry, 2013, 202, 261-268.
156. Walker, E.F.; Walder, D.J.; Reynolds, F. Developmental changes in cortisol secretion in normal and at-risk youth. Dev. Psychopathol, 2001, 13, 721-732.
157. Ajnakina, O.; Borges, S.; Di Forti M.; Patel, Y.; Xu, X.; Green, P.; Stilo, S.A.; Kolliakou, A.; Sood, P.; Marques, T.R.; David, A.S.; Prata, D.; Dazzan, P.; Powell, J.; Pariante, C.; Mondelli, V.; Morgan, C.; Murray, R.M.; Fisher, H.L.; Iyegbe, C. Role of Environmental Confounding in the Association between FKBP5 and First-Episode Psychosis. Front Psychiatry, 2014, 5, 84.
158. Levran, O.; Randesi, M.; Li, Y.; Rotrosen, J.; Ott, J.; Adelson, M.; Kreek, M.J. Drug addiction and stress-response genetic variability: association study in African Americans. Ann. Hum. Genet., 2014, 78, 290-298.
159. Koob, G.F. A role for brain stress systems in addiction. Neuron, 2008, 59, 11-34.
160. Levran, O.; Peles, E.; Randesi, M.; Li, Y.; Rotrosen, J.; Ott, J.; Adelson, M.; Kreek, M.J. Stress-related genes and heroin addiction: a role for a functional FKBP5 haplotype. Psychoneuroendocrinology, 2014, 45, 67-76.
161. McClintick, J.N.; Xuei, X.; Tischfield, J.A.; Goate, A.; Foroud, T.; Wetherill, L.; Ehringer, M.A.; Edenberg, H.J. Stress-response pathways are altered in the hippocampus of chronic alcoholics. Alcohol, 2013, 47, 505-515.
162. Mann, J.J. Currier, D. A review of prospective studies of biologic predictors of suicidal behavior in mood disorders. Arch. Suicide Res., 2007, 11, 3-16.
163. Supriyanto, I.; Sasada, T.; Fukutake, M.; Asano, M.; Ueno, Y.; Nagasaki, Y.; Shirakawa, O.; Hishimoto, A. Association of FKBP5 gene haplotypes with completed suicide in the Japanese population. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2011, 35, 252-256.
164. Pérez-Ortiz, J.M.; Garciá-Gutierrez, M S.; Navarrete, F.; Giner, S.; Manzanares, J. Gene and protein alterations of FKBP5 and glucocorticoid receptor in the amygdala of suicide victims. Psychoneuroendocrinology, 2013, 38, 1251-1258.
165. Brent, D.; Melhem, N.; Turecki, G. Pharmacogenomics of suicidal events. Pharmacogenomics, 2010, 11, 793-807.
166. Kadmiel, M., Cidlowski, J.A. Glucocorticoid receptor signaling in health and disease. Trends Pharmacol. Sci., 2013, 34, 518-530.
167. Rees-Unwin, K.S.; Craven, R.A.; Davenport, E.; Hanrahan, S.; Totty, N.F.; Dring, A.M.; Banks, R.E.; Morgan, J.; Davies, F.E. Proteomic evaluation of pathways associated with dexamethasonemediated apoptosis and resistance in multiple myeloma. Br. J. Haematol., 2007, 139, 559-567.
168. Avellino, R.; Romano, S.; Parasole, R.; Bisogni, R.; Lamberti, A.; Poggi, V.; Venuta, S.; Romano, M.F. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood, 2005, 106, 1400-1406.
169. Matsushita, R.; Hashimoto, A.; Tomita, T.; Yoshitawa, H.; Tanaka, S.; Endo, H.; Hirohata, S. Enhanced expression of mRNA for FK506-binding protein 5 in bone marrow CD34 positive cells in patients with rheumatoid arthritis. Clin. Exp. Rheumatol., 2010, 28, 87-90.
170. Jiang, W.; Cazacu, S.; Xiang, C.; Zenklusen, J.C.; Fine, H.A.; Berens, M.; Armstrong, B.; Brodie, C.; Mikkelsen, T. FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway. Neoplasia., 2008, 10, 235-243.
171. Taipale, M.; Tucker, G.; Peng, J.; Krykbaeva, I.; Lin, Z.Y.; Larsen, B.; Choi, H.; Berger, B.; Gingras, A.C.; Lindquist, S. A quantitative chaperone interaction network reveals the architecture of cellular protein homeostasis pathways. Cell, 2014, 158, 434-448.
172. Cotta-Ramusino, C.; McDonald, E.R.;Hurov, K.; Sowa, M.E.; Harper, J.W.; Elledge, S.J. A DNA damage response screen identifies RHINO, a 9-1-1 and TopBP1 interacting protein required for ATR signaling. Science, 2011, 332, 1313-1317.
173. Gassen, N.C.; Hartmann, J.; Zschocke, J.; Stepan, J.; Hafner, K.; Zellner, A.; Kirmeier, T.; Kollmannsberger, L.; Wagner, K.V.; Dedic, N.; Balsevich, G.; Deussing, J.M.; Kloiber, S.; Lucae, S.; Holsboer, F.; Eder, M.; Uhr, M.; Ising, M.; Schmidt, M.V.; Rein, T. Association of FKBP51 with Priming of Autophagy Pathways and Mediation of Antidepressant Treatment Response: Evidence in Cells, Mice, Humans. PLoS. Med., 2014, 11, e1001755.
174. De Kloet, E. R.; Vreugdenhil, E.; Oitzl, M. S.; Joels, M. (1998). Brain corticosteroid receptor balance in health and disease. Endocr. Rev., 1998, 19, 269-301.
175. Romano, S.; Di Pace A.; Sorrentino, A.; Bisogni, R.; Sivero, L.; Romano, M.F. FK506 binding proteins as targets in anticancer therapy. Anticancer Agents Med. Chem., 2010, 10, 651-656.
176. Schmidt, M.V.; Paez-Pereda, M.; Holsboer, F.; Hausch, F. The prospect of FKBP51 as a drug target. Chem. Med. Chem., 2012, 7, 1351-1359.
177. Gaali, S.; Kirschner, A.; Cuboni, S.; Hartmann, J.; Kozany, C.; Balsevich, G.; Namendorf, C.; Fernandez-Vizarra, P.; Sippel, C.; Zannas, A.S.; Draenert, R.; Binder, E.B.; Almeida, O.F.; Ruhter, G.; Uhr, M.; Schmidt, M. V.; Touma, C.; Bracher, A.; Hausch, F. Selective inhibitors of the FK506-binding protein 51 by induced fit. Nat. Chem. Biol., 2015, 11, 33-37.
178. McConnell, J.R.; Alexander, L.A.; McAlpine, S.R. (2014). A heat shock protein 90 inhibitor that modulates the immunophilins and regulates hormone receptors without inducing the heat shock response. Bioorg. Med. Chem. Lett., 2014, 24, 661-666.
179. Zannas, A.S. Binder, E.B. Gene-environment interactions at the FKBP5 locus: sensitive periods, mechanisms and pleiotropism. Genes Brain Behav., 2014, 13, 25-37.
180. Connell, P.; Ballinger, C. A.; Jiang, J.; Wu, Y.; Thompson, L. J.; Höhfeld, J.; Patterson, C. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell Biol., 2001, 3, 93-96.
181. Wolf, I.M.; Periyasamy, S.; Hinds, T.; Jr.; Yong, W.; Shou, W.; Sanchez, E.R. (2009). Targeted ablation reveals a novel role of FKBP52 in gene-specific regulation of glucocorticoid receptor transcriptional activity. J. Steroid Biochem. Mol. Biol., 2009, 113, 36-45.
182. Morishima, Y.; Kanelakis, K.C.; Silverstein, A.M.; Dittmar, K.D.; Estrada, L.; Pratt, W.B. The Hsp Organizer Protein Hop Enhances the Rate of but Is Not Essential for Glucocorticoid Receptor Folding by the Multiprotein Hsp90-based Chaperone System. J. Biol. Chem., 2000, 275, 6894-6900.
183. Zuo, Z.; Urban, G.; Scammell, J.G.; Dean, N.M.; McLean, T.K.; Aragon, I.; Honkanen, R.E. (1999). Ser/Thr protein phosphatase type 5 (PP5) is a negative regulator of glucocorticoid receptormediated growth arrest. Biochemistry, 1999, 38, 8849-8857.
184. Wang, Z.; Chen, W.; Kono, E.; Dang, T.; Garabedian, M.J. Modulation of glucocorticoid receptor phosphorylation and transcriptional activity by a C-terminal-associated protein phosphatase. Mol. Endocrinol., 2007, 21, 625-634.
185. Paul, A.; Garcia, Y.A.; Zierer, B.; Patwardhan, C.; Gutierrez, O.; Hildenbrand, Z.; Harris, D.C.; Balsiger, H.A.; Sivils, J.C.; Johnson, J.L.; Buchner, J.; Chadli, A.; Cox, M.B. The cochaperone SGTA (small glutamine-rich tetratricopeptide repeat-containing protein alpha) demonstrates regulatory specificity for the androgen, glucocorticoid, and progesterone receptors. J. Biol.Chem., 2014, 289, 15297-15308.
186. Zhao, Y.; Goto, K.; Saitoh, M.; Yanase, T.; Nomura, M.; Okabe, T.; Takayanagi, R.; Nawata, H. Activation function-1 domain of androgen receptor contributes to the interaction between subnuclear splicing factor compartment and nuclear receptor compartment. Identification of the p102 U5 small nuclear ribonucleoprotein particle-binding protein as a coactivator for the receptor. J. Biol.Chem., 2002, 277, 30031-30039.
187. Brychzy, A.; Rein, T.; Winklhofer, K.F.; Hartl, F.U.; Young, J.C.; and Obermann, W.M. Cofactor Tpr2 combines two TPR domains and a J domain to regulate the Hsp70/Hsp90 chaperone system. EMBO J., 2003, 22, 3613-3623.
188. Laenger, A.; Lang-Rollin, I.; Kozany, C.; Zschocke, J.; Zimmermann, N.; Rüegg, J.; Holsboer, F.; Hausch, F.; Rein, T. XAP2 inhibits glucocorticoid receptor activity in mammalian cells. FEBS Lett., 2009, 583, 1493-1498.